| Literature DB >> 27207783 |
Jing Chen1, Lihong Chen2, Philippe Sanseau1, Johannes M Freudenberg1, Deepak K Rajpal3.
Abstract
The gastrointestinal (GI) tract can have significant impact on the regulation of the whole-body metabolism and may contribute to the development of obesity and diabetes. To systemically elucidate the role of the GI tract in obesity, we performed a transcriptomic analysis in different parts of the GI tract of two obese mouse models: ob/ob and high-fat diet (HFD) fed mice. Compared to their lean controls, significant changes in the gene expression were observed in both obese mouse groups in the stomach (ob/ob: 959; HFD: 542). In addition, these changes were quantitatively much higher than in the intestine. Despite the difference in genetic background, the two mouse models shared 296 similar gene expression changes in the stomach. Among those genes, some had known associations to obesity, diabetes, and insulin resistance. In addition, the gene expression profiles strongly suggested an increased gastric acid secretion in both obese mouse models, probably through an activation of the gastrin pathway. In conclusion, our data reveal a previously unknown dominant connection between the stomach and obesity in murine models extensively used in research.Entities:
Keywords: Diet‐induced changes; metabolic diseases; obesity; obesity mechanisms; stomach; transcriptomics
Mesh:
Year: 2016 PMID: 27207783 PMCID: PMC4886165 DOI: 10.14814/phy2.12793
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Figure 1Plots of PCA result based on expression levels of all genes. (A) ob/ob and ob control samples. (B) HFD and normal diet samples. According to this plot, the samples are largely clustered by their tissue types, with ascending colon and descending colon clustered together, duodenum and jejunum clustered together, and stomach and ileum clustered separately.
Number of significantly differentially regulated genes in ob/ob, HFD and both models, with FDR < 0.1 and absolute fold‐change > 1.5
| Tissue | Up‐regulated | Down‐regulated | Opposite regulation in two models | ||||
|---|---|---|---|---|---|---|---|
| ob/ob | HFD | Common | ob/ob | HFD | Common | ||
| Stomach | 711 | 433 | 283 | 248 | 109 | 13 | 3 |
| Duodenum | 57 | 85 | 2 | 16 | 41 | 0 | 5 |
| Jejunum | 17 | 9 | 3 | 5 | 14 | 1 | 1 |
| Ileum | 103 | 76 | 7 | 51 | 36 | 2 | 11 |
| A.colon | 41 | 43 | 3 | 46 | 48 | 2 | 3 |
| D.colon | 17 | 60 | 4 | 30 | 95 | 2 | 1 |
Figure 2(A) Heat map of 1263 differentially expressed genes across different tissues, comparing ob/ob versus ob control samples. The log2 fold‐change profile between ob/ob versus ob control samples for each tissue is used for plotting. (B) Heat map of 926 differentially expressed genes across different tissues, comparing HFD versus normal diet samples. The log2 fold‐change profile between HFD versus control samples for each tissue was used for plotting. Yellow denotes up, and blue denotes downregulation in ob/ob or HFD. Genes and samples are represented by rows and columns, respectively. Genes with FDR < 0.1 and absolute fold‐change > 1.5 in any tissues are shown in the heat map and are clustered by hierarchical clustering.
Over‐represented pathways in ob/ob mouse model. Numbers are counts of differentially regulated genes in each pathway in the specified tissue
| Pathway | Stomach | Duodenum | Jejunum | Ileum | A.colon | D.colon |
|---|---|---|---|---|---|---|
| (A) Pathways over‐represented in up‐regulated genes | ||||||
| Blood coagulation | 15 | 0 | 0 | 0 | 0 | 0 |
| Bile acids regulation of glucose and lipid metabolism via FXR | 10 | 0 | 0 | 3 | 0 | 0 |
| Glycine, serine, cysteine and threonine metabolism | 10 | 0 | 0 | 0 | 0 | 0 |
| Linoleic acid | 6 | 0 | 0 | 0 | 0 | 0 |
| FXR‐dependent negative‐feedback regulation of bile acids concentration | 6 | 0 | 0 | 0 | 0 | 0 |
| Platelet microparticle generation | 14 | 0 | 0 | 0 | 0 | 0 |
| Phenylalanine metabolism | 7 | 0 | 0 | 0 | 0 | 0 |
| PXR sigling via cross‐talk | 6 | 0 | 0 | 2 | 0 | 0 |
| Propiote metabolism p.1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Leucine, isoleucine and valine metabolism.p.2 | 7 | 0 | 0 | 0 | 0 | 0 |
| Tight junctions | 11 | 0 | 0 | 0 | 0 | 0 |
| (L)‐Alanine, (L)‐cysteine, and (L)‐methionine metabolism | 6 | 0 | 0 | 0 | 0 | 0 |
| Sulfur metabolism | 6 | 0 | 0 | 0 | 0 | 0 |
| FXR‐regulated cholesterol and bile acids cellular transport | 6 | 0 | 0 | 0 | 0 | 0 |
| Triacylglycerol metabolism p.2 | 3 | 3 | 0 | 0 | 0 | 0 |
| Glycolysis and gluconeogenesis p.1 | 0 | 0 | 0 | 4 | 0 | 0 |
| Fructose metabolism | 5 | 0 | 0 | 4 | 0 | 0 |
| GnRH sigling | 0 | 0 | 0 | 6 | 0 | 0 |
| Aldosterone‐mediated regulation of EC sodium transport | 0 | 0 | 0 | 2 | 2 | 3 |
| Impaired NO sigling in CF airways | 0 | 0 | 0 | 0 | 0 | 2 |
| (B) Pathways over‐represented in down‐regulated genes | ||||||
| Huntingtin‐depended transcription deregulation in Huntington's Disease | 5 | 0 | 0 | 0 | 0 | 0 |
| Antigen presentation by MHC class II | 4 | 0 | 0 | 0 | 0 | 0 |
| IFN alpha/beta sigling pathway | 0 | 0 | 0 | 0 | 0 | 4 |
| Antiviral actions of Interferons | 4 | 0 | 0 | 0 | 0 | 4 |
| IFN gamma sigling pathway | 0 | 0 | 0 | 0 | 0 | 3 |
*indicates FDR < 0.1 and # P‐value < 0.05 for the significance of the pathway in the specified tissue.
Over‐represented pathways in HFD mouse model. Numbers are counts of differentially regulated genes in each pathway in the specified tissue
| Pathway | Stomach | Duodenum | Jejunum | Ileum | A.colon | D.colon |
|---|---|---|---|---|---|---|
| (A) Pathways over‐represented in up‐regulated genes | ||||||
| Leucine, isoleucine and valine metabolism.p.2 | 8 | 0 | 0 | 0 | 0 | 0 |
| Propiote metabolism p.1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Tight junctions | 9 | 0 | 0 | 0 | 0 | 0 |
| Blood coagulation | 6 | 0 | 0 | 0 | 0 | 0 |
| (L)‐Alanine, (L)‐cysteine, and (L)‐methionine metabolism | 5 | 0 | 0 | 0 | 0 | 0 |
| Populations of skin dendritic cells involved in contact hypersensitivity | 0 | 0 | 0 | 5 | 0 | 0 |
| Role of B cells in SLE | 0 | 2 | 0 | 7 | 0 | 0 |
| Antiviral actions of Interferons | 6 | 0 | 0 | 5 | 0 | 0 |
| Th17 cell differentiation | 0 | 0 | 0 | 5 | 0 | 0 |
| IL‐22 sigling pathway | 0 | 0 | 0 | 5 | 0 | 0 |
| NK cells in allergic contact dermatitis | 0 | 0 | 0 | 5 | 0 | 0 |
| Th17 cells in CF (mouse model) | 0 | 0 | 0 | 5 | 0 | 0 |
| Differences between Langerhans cells and dermal dendritic cells in allergic | 0 | 0 | 0 | 4 | 0 | 0 |
| Th17, Th22 and Th9 cell differentiation | 0 | 0 | 0 | 5 | 0 | 2 |
| ive CD4+ T cell differentiation | 0 | 0 | 0 | 5 | 0 | 2 |
| Th1 and Th2 cell differentiation | 0 | 0 | 0 | 5 | 0 | 0 |
| Role of HMGB1 in dendritic cell maturation and migration | 0 | 0 | 0 | 4 | 0 | 2 |
| Th17 cells in CF | 0 | 0 | 0 | 5 | 0 | 0 |
| Regulatory T cells in human allergic contact dermatitis | 0 | 0 | 0 | 3 | 0 | 0 |
| LRRK2 and immune function in Parkinson's disease | 0 | 0 | 0 | 4 | 0 | 0 |
| Mechanisms of hapten presentation to T cells in allergic contact dermatitis | 0 | 0 | 0 | 3 | 0 | 0 |
| Differentiation of tural regulatory T cells | 0 | 0 | 0 | 4 | 0 | 0 |
| NF‐AT sigling and leukocyte interactions | 0 | 0 | 0 | 5 | 0 | 0 |
| Antigen presentation by MHC class II | 0 | 0 | 0 | 3 | 0 | 0 |
| Differentiation and clol expansion of CD8+ T cells | 0 | 0 | 0 | 4 | 0 | 0 |
| SLE genetic markers in B cell specific pathways | 0 | 3 | 0 | 5 | 0 | 0 |
| Generation of memory CD4+ T cells | 0 | 0 | 0 | 4 | 0 | 2 |
| Role of IL‐17‐producing T cells in allergic contact dermatitis | 0 | 0 | 0 | 3 | 0 | 0 |
| T regulatory cell‐mediated modulation of antigen‐presenting cell functions | 0 | 0 | 0 | 4 | 0 | 0 |
| Role of cell adhesion in vaso‐occlusion in Sickle cell disease | 5 | 0 | 0 | 4 | 0 | 0 |
| CD8+ Tc1 cells in allergic contact dermatitis | 0 | 0 | 0 | 3 | 0 | 0 |
| Regulatory T cells in murine model of contact hypersensitivity | 0 | 0 | 0 | 3 | 0 | 0 |
| T cell receptor sigling pathway | 0 | 0 | 0 | 4 | 0 | 0 |
| NFAT in immune response | 0 | 0 | 0 | 4 | 0 | 0 |
| Role of keratinocytes and Langerhans cells in skin sensitization | 0 | 0 | 0 | 3 | 0 | 0 |
| G‐protein sigling_N‐RAS regulation pathway | 0 | 0 | 0 | 3 | 0 | 0 |
| Inflammatory mechanisms of pancreatic | 0 | 0 | 0 | 4 | 0 | 3 |
| HSP60 and HSP70/ TLR sigling pathway 0 0 | 0 | 0 | 0 | 4 | 0 | 3 |
| C3a sigling | 0 | 0 | 0 | 4 | 0 | 0 |
| Reproduction_GnRH sigling | 0 | 0 | 0 | 0 | 0 | 6 |
| (B) Pathways over‐represented in down‐regulated genes | ||||||
| Cholesterol biosynthesis | 4 | 0 | 0 | 0 | 0 | 2 |
| CAR‐mediated direct regulation of xenobiotic metabolizing enzymes | 0 | 7 | 0 | 0 | 2 | 2 |
| Benzo[a]pyrene metabolism | 0 | 5 | 4 | 2 | 0 | 0 |
| 2‐Naphthylamine and 2‐Nitronaphtalene metabolism | 0 | 4 | 2 | 0 | 0 | 0 |
| Retinol metabolism | 2 | 5 | 3 | 3 | 0 | 0 |
| Glutathione metabolism | 0 | 5 | 2 | 0 | 3 | 0 |
| Naphthalene metabolism | 0 | 4 | 3 | 0 | 0 | 0 |
| Acetaminophen metabolism | 0 | 3 | 0 | 0 | 0 | 0 |
| Estradiol metabolism | 0 | 3 | 2 | 0 | 0 | 0 |
| Glutathione metabolism | 0 | 4 | 0 | 0 | 2 | 0 |
| Estradiol metabolism | 0 | 3 | 2 | 0 | 0 | 0 |
| Androstenedione and testosterone biosynthesis and metabolism p.1 | 0 | 3 | 2 | 0 | 0 | 0 |
| Serotonin ‐ melatonin biosynthesis and metabolism | 0 | 3 | 0 | 0 | 0 | 0 |
| PXR‐mediated direct regulation of xenobiotic metabolizing enzymes | 0 | 3 | 0 | 2 | 0 | 0 |
| Vitamin K metabolism | 0 | 2 | 0 | 0 | 0 | 0 |
| 1‐Naphthylamine and 1‐Nitronaphtalene metabolism | 0 | 2 | 0 | 0 | 0 | 0 |
| Aryl hydrocarbon receptor signaling | 0 | 3 | 0 | 2 | 3 | 3 |
| Estrone metabolism | 0 | 2 | 0 | 0 | 0 | 0 |
| Histamine metabolism | 0 | 2 | 0 | 0 | 0 | 0 |
| Estrone metabolism | 0 | 2 | 0 | 0 | 0 | 0 |
| The metaphase checkpoint | 0 | 0 | 0 | 0 | 0 | 12 |
| Role of APC in cell cycle regulation | 0 | 0 | 0 | 0 | 0 | 13 |
| Chromosome condensation in prometaphase | 0 | 0 | 0 | 0 | 0 | 10 |
| Spindle assembly and chromosome separation | 0 | 0 | 0 | 0 | 0 | 11 |
| Role of Nek in cell cycle regulation | 0 | 0 | 0 | 0 | 0 | 7 |
| Initiation of mitosis | 0 | 0 | 0 | 0 | 0 | 6 |
| Progesterone‐mediated oocyte maturation | 0 | 0 | 0 | 0 | 0 | 6 |
| Sister chromatid cohesion | 0 | 0 | 0 | 0 | 0 | 4 |
| Abnormalities in cell cycle in SCLC | 0 | 0 | 0 | 0 | 0 | 4 |
| Nucleocytoplasmic transport of CDK/Cyclins | 0 | 0 | 0 | 0 | 0 | 3 |
*indicates FDR < 0.1 and # P‐value < 0.05 for the significance of the pathway in the specified tissue.
Spearman's correlation coefficients of normalized expression profiles between all tissues of the two mouse models
| Hfd Stomach | Hfd Duodenum | Hfd Jejunum | Hfd Ileum | Hfd A.colon | Hfd D.colon | |
|---|---|---|---|---|---|---|
| Ob Stomach | 0.34 | 0 | −0.12 | −0.04 | −0.22 | −0.1 |
| Ob Duodenum | 0 | −0.14 | −0.06 | −0.16 | −0.17 | −0.23 |
| Ob Jejunum | 0.04 | −0.01 | −0.05 | −0.03 | −0.18 | −0.03 |
| Ob Ileum | 0.03 | 0.05 | 0.08 | 0.01 | −0.08 | 0.03 |
| Ob A.colon | 0.05 | 0 | 0 | 0.05 | −0.11 | −0.06 |
| Ob D.colon | −0.05 | −0.08 | −0.11 | 0 | −0.23 | −0.08 |
Figure 3(A) Heat map of 1749 differentially expressed genes across different tissues in the two mouse models. The log2 fold‐change profile between ob versus ob control, or HFD versus normal diet is used. (B) Heat map of 1221 differentially expressed genes across different biological replicates of stomach in the two mouse models. The log2 fold‐change profile of each ob/ob sample normalized to ob control, or HFD sample normalized to normal diet is used. Yellow denotes up, and blue denotes downregulation in ob/ob. Genes and samples are represented by rows and columns, respectively. Genes with FDR < 0.1 and absolute fold‐change > 1.5 in any tissues are shown in the heat map and are clustered by hierarchical clustering.
Significant pathways of commonly up‐regulated genes in ob/ob and HFD
| Pathway | Counts of up‐regulated genes |
|---|---|
| Tight junctions | 9 |
| Blood coagulation | 6 |
| Regulation of actin cytoskeleton by Rho GTPases | 7 |
| Propionate metabolism p.1 | 4 |
| Stimulation of gastric acid secretion in gastric cancer | 7 |
| Leucine, isoleucine and valine metabolism.p.2 | 5 |
| GPCRs in platelet aggregation | 9 |
| Alpha‐1A adrenergic receptor‐dependent inhibition of | 5 |
*FDR < 0.1.
Genes with known obesity association
| GeneID | Gene symbol | Gene name | ob/ob | HFD |
|---|---|---|---|---|
| 58991 | Ghrl | Ghrelin | 8.86 | 14.35 |
| 18778 | Pla2g1b | Phospholipase A2, group IB, pancreas | 9.32 | 11.49 |
| 22139 | Ttr | Transthyretin | 8.88 | 8.44 |
| 19662 | Rbp4 | Retinol binding protein 4, plasma | 2.18 | 1.90 |
| 21784 | Tff1 | Trefoil factor 1 | 4.17 | 2.97 |
| 21785 | Tff2 | Trefoil factor 2 (spasmolytic protein 1) | 7.24 | 5.09 |
| 69060 | Pnlip | Pancreatic lipase | 2.56 | −1.56 |
| 18946 | Pnliprp1 | Pancreatic lipase related protein 1 | 9.34 | 3.59 |
| 18947 | Pnliprp2 | Pancreatic lipase‐related protein 2 | 9.84 | 5.96 |
| 20750 | Spp1 (Opn) | Secreted phosphoprotein 1 | 6.47 | 6.54 |
| 12652 | Chga | Chromogranin A | 5.25 | 4.79 |
*FDR < 0.10, # P < 0.05.
Gastric acid related genes
| GeneID | Gene symbol | Gene name | ob/ob | HFD |
|---|---|---|---|---|
| 11944 | Atp4a | ATPase, H+/K+ exchanging, gastric, alpha polypeptide | 10.11 | 9.96 |
| 11945 | Atp4b | ATPase, H+/K+ exchanging, beta polypeptide | 7.88 | 10.74 |
| 16535 | Kcnq1 | Potassium voltage‐gated channel, subfamily Q, member 1 | 3.92 | 4.41 |
| 246133 | Kcne2 | Potassium voltage‐gated channel, Isk‐related subfamily, gene 2 | 5.71 | 9.82 |
| 209195 | Clic6 | Chloride intracellular channel 6 | 7.52 | 11.71 |
| 20499 | Slc12a7 | Solute carrier family 12, member 7 | 2.08 | 2.17 |
| 20535 | Slc4a2 | Solute carrier family 4 (anion exchanger), member 2 | 2.35 | 2.42 |
| 208890 | Slc26a7 | Solute carrier family 26, member 7 | 1.44 | 1.65 |
| 226999 | Slc9a2 | Solute carrier family 9 (sodium/hydrogen exchanger), member 2 | 1.86 | 1.96 |
| 20544 | Slc9a1 | Solute carrier family 9 (sodium/hydrogen exchanger), member 1 | 1.58 | 1.27 |
| 20496 | Slc12a2 | Solute carrier family 12, member 2 | 1.59 | 1.32 |
| 11931 | Atp1b1 | ATPase, Na+/K+ transporting, beta 1 polypeptide | 2.06 | 2.20 |
| 17829 | Muc1 | Mucin 1, transmembrane | 5.72 | 7.23 |
| 17833 | Muc5ac | Mucin 5, subtypes A and C, tracheobronchial/gastric | 7.85 | 3.66 |
| 14459 | Gast | Gastrin | 1.17 | −1.27 |
| 225642 | Grp | Gastrin releasing peptide | −1.53 | −1.46 |
| 12426 | Cckbr | Cholecystokinin B receptor | 1.60 | 1.31 |
| 11829 | Aqp4 | Aquaporin 4 | 1.87 | 2.67 |
| 11839 | Areg | Amphiregulin | 3.23 | 1.94 |
| 15186 | Hdc | Histidine decarboxylase | 2.98 | 2.13 |
| 214084 | Slc18a2 | Solute carrier family 18 (vesicular monoamine), member 2 | 2.35 | 3.22 |
| 12652 | Chga | Chromogranin A | 5.25 | 4.79 |
| 12349 | Car2 | Carbonic anhydrase 2 | 1.53 | 1.64 |
| 15466 | Hrh2 | Histamine receptor H2 | 1.65 | 1.78 |
| 14465 | Gata6 | GATA binding protein 6 | 2.38 | 2.34 |
| 20604 | Sst | Somatostatin | 4.61 | 6.97 |
| 20606 | Sstr2 | Somatostatin receptor 2 | 2.06 | 1.39 |
*FDR < 0.10, # P < 0.05.